23 March, 2018
Chordate enrolls first patient in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the preventive treatment of chronic migraine.
Kista, Sweden, March 23, 2018 — Chordate Medical Holding AB’s (publ) (“Chordate”), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and migraine, today announced that the first patient was enrolled in the Chordate’s clinical study of its Kinetic Oscillation Stimulation System S211 (KOS-treatment), Chordate’s investigative product, in patients with diagnosed chronic migraine (≥15 days/month of headache, whereof >8 days with migraine).“Enrolling the first patient in our multicenter migraine study marks an important milestone for the company as we work our way towards bringing our S211 product to the market. I believe that our proprietary non-pharmaceutical preventive treatment method has great potential to make huge difference for many patients with chronic headache problems around the world”, said Anders Weilandt, CEO of Chordate.The randomized, placebo-controlled, double-blind, multicenter study is being conducted at four neurology clinics in Germany. The study intends to enroll up to 140 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment, with the primary endpoint to detect mean change from baseline (4-week screening period) in monthly headache days with moderate to severe intensity, in a 4-week performance assessment period. Patients in the KOS arm will receive active treatment from the S211, while patients receiving placebo treatment will be given a validated sham treatment from the same equipment.
For more information, please contact:Anders Weilandt, CEOanders.firstname.lastname@example.orgPhone: +46 (0) 733 87 42 77
Information:This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact person above for publication on March 23, 2018 at. 08:30 CET.
TO THE EDITORSAbout ChordateChordate Medical Holding AB (publ) is a medical technology company that during ten years has developed, patented and CE-marked a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product system including treatments through its own sales organization as well as distributors to clinics and hospitals, which in their turn treat patients. Read more at www.chordate.com. Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company’s mentor and liquidity guarantee at NGM Nordic MTF.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.